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Abstract No guidelines for performing and presenting
the results of studies on patients with medication overuse
headache (MOH) exist. The aim of this study was to review
long-term outcome measures in follow-up studies pub-
lished in 2006 or later. We included MOH studies with
[6 months duration presenting a minimum of one prede-
fined end point. In total, nine studies were identified. The
1,589 MOH patients (22% men) had an overall mean fre-
quency of 25.3 headache days/month at baseline. Headache
days/month at the end of follow-up was reported in six
studies (mean 13.8 days/month). The decrease was more
pronounced for studies including patients with migraine
only (-14.6 days/month) compared to studies with the
original diagnoses of migraine and tension-type headache
(-9.2 days/month). Six studies reported relapse rate (mean
of 26%) and/or responder rate (mean of 28%). Medication
days/month and change in headache index at the end of
follow-up were reported in only one and two of nine
studies, respectively. The present review demonstrated a
lack of uniform end points used in recently published fol-
low-up studies. Guidelines for presenting follow-up data on
MOH are needed and we propose end points such as
headache days/month, medication days/month, relapse rate
and responder rate defined as C50% reduction of headache
frequency and/or headache index from baseline.
Keywords Medication overuse headache  Follow-up 
Outcome parameters  Relapse rate  Responders
Introduction
Worldwide, approximately 1–2% of the adult general
population suffers from chronic headache (C15 days/
month) combined with medication overuse [1–6]. The
optimal method of treating the many patients with medi-
cation overuse headache (MOH) is still controversial,
mainly due to lack of placebo-controlled, double-blind,
randomized clinical trials [7]. No established consensus for
treatment strategies exists for patient with MOH. As a
consequence, the therapeutic strategies for the acute phase
of detoxification and the use of preventive treatment differ
widely between studies [8].
Most previous follow-up studies of patients with MOH
are case series and non-randomized studies, which are
difficult to interpret. The lack of high-quality studies makes
it difficult to draw firm conclusions regarding the man-
agement of MOH [8]. During the last two decades, several
guidelines for controlled treatment trials for patients with
migraine and tension-type headache have been published
[9–11], also emphasizing the need of uniform end points.
However, no guidelines on performing and presenting the
result of studies on MOH patients exist. Due to the lack of
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guidelines, it may be of relevance to review the type of end
points published in recent follow-up studies of MOH
patients.
The aim of this study was to analyze and summarize the
long-term outcome measures of MOH patients included in
follow-up studies published in 2006 or later.
Methods
Follow-up studies of patients with MOH published in
English were identified through PubMed by searching for
relevant publications between January 2006 and December
2009. We used the search terms ‘‘medication overuse
headache’’ combined with ‘‘follow-up.’’ References listed
in relevant publications were also examined. All studies
were first screened for various aspects of methodology and
design, and type of content, to select studies of interest for
our purpose. Studies on MOH patients who underwent one
type of intervention were labeled case series, whereas
studies including at least two types of interventions were
labeled controlled studies. We included studies fulfilling
the following four minimum criteria:
(1) published in 2006 or later. Recently published studies
were preferred because the majority of these studies
included patients fulfilling the Headache Classifica-
tion Committee of the International Headache Society
from 2004 (ICDH-2) or later modified versions [12–
14];
(2) [6 months’ duration of follow-up;
(3) at least two of the following characteristics mentioned
explicitly at baseline: primary headache type, head-
ache days/month and/or medication days/month;
(4) at least one of the following end points mentioned
explicitly at follow-up: headache days/month, reduc-
tion of headache frequency from baseline, medication
days/month, reduction of medication days from
baseline, responder rate defined as the proportion of
individuals with C50% reduction of headache fre-
quency from baseline [10], or relapse rate defined as
the proportion of individuals with the diagnosis of
MOH at the end of follow-up among subjects with
‘‘successful withdrawal.’’ In this context patients with
successful withdrawal were defined as those not
overusing medication after the withdrawal period,
regardless of whether they experienced reduction of
headache frequency or not.
Statistics
Mean values of the total group of participants were presented
if available. If mean values of, for e.g., three subgroups were
presented, mean values for the total group were calculated by
the following formula: (days/month 9 number of partici-
pants in group A ? days/month 9 number of participants in
group B ? days/month 9 number of participants in group
C) divided by total number of participants in group A, B and
C. Mean reduction of headache days/month (as percentage)
from baseline was also calculated.
Results
Initially, 33 studies were identified by the PubMed search.
This was reduced to 28 unique studies after removing
multiple publications based on the same patients [15–19].
Overall, nine follow-up studies, all clinic-based, fulfilled
the four criteria of the present review. To optimize com-
parisons between studies, 12 months follow-up data were
preferred in one study, although 3- and 5-year follow-up
data were also available [19]. Five studies included only
MOH patients who had had migraine before developing
MOH, whereas the remaining four studies also included
patient who had had TTH (Table 1) [15, 20–27]. Four
follow-up studies were case series without controls [20–22,
26]: one retrospective [20] and three prospective studies
[21, 22, 26]. The remaining five studies were categorized as
controlled studies with (n = 3) [23–25] or without con-
firmed randomization (n = 2) [15, 27] (Table 1).
Headache diary was used in five studies during the
follow-up [20, 22–25] and most likely used, although not
explicitly stated, in two additional studies [15, 27]. In eight
studies (Table 1) [15, 21–27], 12-month follow-up data
were available. Two Italian studies used the criteria for
chronic migraine proposed by Silberstein and Lipton in
2000 [15, 22], whereas the remaining patients fulfilled the
Headache Classification Committee of the International
Headache Society from 2004 (ICDH-2) [20, 23, 25, 27] or
later modified versions [21, 24, 26]. Although the specific
treatment protocol differed widely between the nine stud-
ies, all studies included abrupt withdrawal as a part of the
protocol (Table 2). Prophylactic treatment was initiated
during the first week in the majority of studies (range
1–90 days) (Table 2).
The 1,589 MOH patients (22% men) included in the
nine different studies had an overall mean of 25.3 headache
days per month (range 22.5–27.0) at baseline. Headache
days at the end of follow-up were reported in six studies
(n = 582, mean follow-up duration 11.3 months, mean
-13. 8 days/month = 45% decrease from baseline) [15,
20, 22, 24, 25, 27]. The mean decrease was more
pronounced for the studies including patients with migraine
only (n = 290, mean follow-up duration 12 months,
-14.6 days/month = 56% decrease from baseline) [15, 22,
27] than among those with migraine and TTH (n = 29,
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mean follow-up duration 10.7 months, -9.2 days/month =
36% decrease from baseline) [20, 24, 25]. The response
rate and relapse rate were reported in only three [20, 24,
25] and four studies [21, 23, 25, 26], respectively, with a
mean of 28 and 26% (Table 3). Medication days/month at
the end of follow-up was reported in one study only [24],
whereas two studies revealed information about change in
the headache index at follow-up compared to baseline (data
not given) [24, 25].
Discussion
Study design and treatment strategy differ widely between
the studies, and direct comparisons should be done with
caution. However, in a recent review it was suggested that
differences in withdrawal therapy strategy seem to have no
major impact on long-term outcome [8]. If true, an overall
45% reduction in headache days and a 28% response rate
during 1 year should be expected for the group of MOH
patients in an open-labeled setting. However, the tendency
of remission or worsening over time must be taken into
account since these factors may overestimate the effect of
treatment [28]. It should be emphasized that the lack of
control group in all studies (except one) increases the risk
that these results may be explained, at least in part, by the
natural history or regression from the mean. These flaws
may be avoided in randomized, double-blind, placebo-
controlled studies. In one placebo-controlled study evalu-
ating the efficacy of topiramate without withdrawal, a more












2006 [20] Denmark 337 (27) 17–86 Yes 8 Retrospective case series
2007 [21] Serbia 240 (24) 17–76 Yes 12 Case series
2007 [22] Italy 106 (18) 19–71 No 12f Case series
2008 [23] Italy 118 (16) – No 12 Randomized controlleda
2009 [24] Norway 61 (39) 18–70 Yes 12 Randomized controlledb
2009 [25] Norway 100 (26) 18–70 Yes 12 Double-blind RCTc ? randomized controlledc
2009 [26] Italy 215 (19) – No 12 Case series
2009 [27] Italy 93 (–) – No 12 Controlledd
2009 [15] Italy 260 (–) – No 12 Controllede
a Three groups: advice alone versus structured detoxification as in- or outpatient
b Three groups: prophylactic treatment from the start without detoxification versus standard outpatient detoxification program without pro-
phylactic treatment from the start versus no specific treatment (controls)
c Two groups: placebo-controlled, double-blind randomized controlled trial (RCT) evaluating efficacy of prednisolone on withdrawal headache
followed by an controlled design evaluating long-term outcome of patients treated by neurologist versus GP
d Two groups; randomization not stated: behavioral plus pharmacological treatment versus pharmacological treatment only
e Two groups, randomization not stated: inpatient versus day-hospital withdrawal treatment
f Data on 3 and 5 years follow-up also available
Table 2 Initial treatment strategies
Study, reference Abrupt withdrawal? In- or outpatient Days at hospital Infusion therapy? Onset of preventive drugs
2006 [20] Yes Outpatient 0 No After 2 months
2007 [21] Yes In- or outpatient 8 Yes During the first weeks?b
2007 [22] Yes Inpatient 10 Yes Day 6
2008 [23] Yes Inpatient 8 Yes Day 1
2009 [24] Yesa Outpatient 0 No Day 1 or after 3 months
2009 [25] Yes Inpatient 3 No After 1 months
2009 [26] Yes Inpatient 10 Yes Day 4 or 5
2009 [27] Yes Day patient 5 Yes Day 5?b
2009 [15] Yes In- or day patient 7 Yes Day 6
a Abrupt withdrawal in one out of three groups
b Incomplete information
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moderate decrease in headache days/month (approximately
25%) was found among MOH patients with chronic
migraine [29].
The most important finding in the present review was a
lack of uniform end points used in the nine follow-up studies.
Headache days/month was the most commonly presented,
followed by relapse rate and/or responder rate. Surprisingly,
only two studies explicitly reported medication days/month
at baseline [24, 26] and only one study did so at the end of
follow-up [24], although this was crucial when considering
the diagnosis of MOH and relapse rate. Although not clearly
stated, one may assume that most studies had collected
information about medication days/month at baseline
according to MOH diagnosis based on ICDH-2 or later
modified versions. Less informative than medication days/
month is the total number of medication doses consumed per
month that was reported in four studies [15, 22, 23, 27]. The
definition of responders varied between studies. In the study
by Rossi et al. [23], responders were defined as those who
had headache\15 days per month and intake of symptom-
atic medication\10 days/month 2 month after withdrawal
treatment. However, using this definition (although it fulfills
the ICDH-2 criteria), patients may be defined as responders
even with a minor reduction in headache and intake of
medication. In our opinion defining a responder as a patient
with C50% reduction of headache frequency from baseline
is more informative, although other definitions, e.g., C25%
reduction of headache frequency from baseline, can be
clinically meaningful for MOH patients [10]. Furthermore,
for MOH patients headache index rather than headache days
may more correctly reflect the total suffering [11]. Two
studies had included such data based on frequency, duration
and intensity [24] or frequency and intensity (named mean
headache in the publication) [25] recorded in headache
diaries. One may still discuss what the optimal definition of a
responder is, but we would favor studies on MOH treatment
that aim at C50% reduction in headache index from baseline.
This was used as a secondary end point in one study [25]. In
accordance, headache index as a primary efficacy measure
has been proposed in the revised version of the guidelines for
controlled trials of prophylactic drugs in chronic tension-
type headache [11]. However, for headache frequency one
should acknowledge that less ambitious definition of end
points, e.g., those with C25% reduction of headache index
from baseline, can be clinically meaningful [10].
In one out of the four studies reporting relapse rates [21,
23, 25, 26], the calculation was restricted to individuals
who had an improvement of headache at follow-up after
2 months [23]. However, in the study by Bøe et al. [25], a
much lower relapse rate at 12 months follow-up was found
among individuals with C50% improvement score at
3 months follow-up than among those without such
improvement (4 vs. 28%). Thus, a higher relapse rate may
be expected if individuals with no or some improvement of
headache frequency after successful withdrawal are inclu-
ded in the analysis.
The review demonstrated a lack of uniform end points in
recently published follow-up studies of patient with MOH.





















2006 [20] 162/337 (48) 27 8 15e – – 67/337b (20) –
2007 [21] – 24.6 12 – – – – 95/240 (39.6)
2007 [22] 22/106 (21) 26.1 12 11.5 – – – –
2008 [23] 37/118 (31) 26.8 12 – – – – 17/83 (20.5)
2009 [24] 5/61 (8) 24.1 12b 17.1e 23.2 8.0 14/41c (34) –
2009 [25] 20/100 (20) 25.4 12 16.7e – – 27/93d (29) 16/80 (20)
2009 [26] 43/215 (20) 22.5 12 – 21.6 – – 38/172 (22)
2009 [27] 36/93 (39) 26.2 12 12.0 – – – –
2009 [15] 111/260 (43) 25.3 12 10.4 – – – –
Number 8 9 9 6 2 1 3 4
Mean 29 25.3 11.6 13.8 – – 28 25.5
a Calculation of response rate (proportion of individuals with C50% reduction in headache frequency from baseline) differ between the three
studies with respect to (a) number of participants included in the analysis and (b) time interval before evaluation
b Analysis of 337 participants (all included) evaluated after a mean of 8 months
c Analysis of 41 individuals evaluated after 12 months (20 controls excluded because of 5 months follow-up duration)
d Analysis of 93 individuals evaluated 3 months after withdrawal
e TTH patients included
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If possible, the evaluation of long-term outcome of patient
with MOH should be based on headache diary information
preferentially including data on headache days/month,
headache intensity and medication days/month. We rec-
ommend that at the end of follow-up, minimum headache
days/month and medication days/month are included, since
these end points are needed to calculate relapse rate. In
addition, we recommend that headache intensity and attack
duration are included and that the responder rate is defined
as C50% reduction of headache frequency and/or headache
index from baseline. However, including end points such as
C25% reduction of headache frequency and/or headache
index may add useful information to the final selection of
end points that should be preferred in the future. There is a
need for increasing awareness of methodological issues in
clinical follow-up studies for MOH. Guidelines for MOH
studies including use of end points are needed.
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